The Mid-term Plan of the Pharmaceuticals and Medical Devices Agency (PMDA) (authorized under MHLW-PFSB No. 0331002 dated March 31, 2009) sets a target for the total review time for new drugs, aiming at a median time of 12 months for standard review products. The target needs to be achieved through efforts by both the regulatory authorities and applicants.